KRUZONTRO Trademark

Trademark Overview


On Friday, December 9, 2022, a trademark application was filed for KRUZONTRO with the United States Patent and Trademark Office. The USPTO has given the KRUZONTRO trademark a serial number of 97711698. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Friday, May 31, 2024. This trademark is owned by Eli Lilly and Company. The KRUZONTRO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative co...
kruzontro

General Information


Serial Number97711698
Word MarkKRUZONTRO
Filing DateFriday, December 9, 2022
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateFriday, May 31, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 24, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, pharmaceutical preparations for the treatment of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, blood diseases and disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cluster headaches, Coronavirus disease, Crohn's disease, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, heart failure, inflammation and inflammatory diseases and disorders, inflammatory bowel disease, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, metabolic diseases and disorders, migraines, multiple sclerosis, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, Psoriasis, Psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, vascular diseases

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateFriday, May 31, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameEli Lilly and Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Party NameEli Lilly and Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressIndianapolis, IN 46285

Trademark Events


Event DateEvent Description
Tuesday, December 13, 2022NEW APPLICATION ENTERED
Saturday, January 7, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, September 13, 2023ASSIGNED TO EXAMINER
Friday, September 15, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 4, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, October 24, 2023PUBLISHED FOR OPPOSITION
Tuesday, October 24, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 19, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Thursday, May 30, 2024TEAS EXPRESS ABANDONMENT RECEIVED
Friday, May 31, 2024ABANDONMENT - AFTER PUBLICATION
Friday, May 31, 2024ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION